Table 1 Clinical data of 937 PV and ET patients.
From: QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms
ET patients (490) [range] – (%) | PV patients (447) [range] – (%) | |
|---|---|---|
Sex, male/female | 145/345 (26/74) | 214/233 (48/52) |
Age at diagnosis, years | 47 [25–85] | 46 [25–84] |
Mutational status: | Available for 424 | Available for 420 |
JAK2 | 253 (59.7) | 405 (96.4) |
MPL | 7 (1.6) | / |
CALR | 117 (27.6) | / |
Triple-negative | 47 (11.1) | 15 (3.6) |
VAF, % | Available for 34 13 [1–41] % a | Available for 39 39 [7–98] %** |
Risk at diagnosis | ||
Low | 355 (72.4) | 312 (69.8) |
High | 135 (27.5) | 135 (31.2) |
QRISK3 score at diagnosis | 3.2 [0.1–40.6] % | 3.5 [0.1–41] % |
Primary MPN-specific approach* | ||
Watch and wait/venesection | 292 (59.5) | 276 (61.7) |
Hydroxyurea | 143 (29.2) | 106 (23.7) |
Ruxolitinib | 11 (2.3) | 10 (2.2) |
Interferon-α | 44 (9) | 55 (12.4) |
Thrombosis history at/before diagnosis | 64 (13.1) | 84 (18.8) |
Thrombosis during follow-up | ||
Events | 52 events in 46 patients (9.4) | 73 events in 62 patients (13.9) |
Time to thrombosis, months | 39 [2–324] | 38 [1–232] |
Thrombosis site: | ||
Pulmonary embolism | 2 (3.8) | 5 (6.8) |
Myocardial infarction | 8 (15.4) | 16 (21.9) |
Cerebrovascular accident | 14 (26.9) | 27 (37.1) |
Portal vein | 4 (7.7) | 5 (6.8) |
Other VTE | 23 (44.3) | 20 (27.4) |
Other arterial | 1 (1.9) | / |
Transformed to PET/PPV MF | 9 (1.8) | 9 (2) |
Status: | ||
Alive | 389 (79.4) | 382 (85.4) |
Death | 25 (5.1) | 16 (3.6) |
Lost at follow-up | 76 (15.5) | 49 (11) |
Median follow-up, months | 85 [3–481] | 95 [3–405] |
